Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Leukemia

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 499 articles:
HTML format
Text format



Single Articles


    February 2020
  1. THOMSON DW, Shahrin NH, Wang PPS, Wadham C, et al
    Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia.
    Leukemia. 2020 Feb 19. pii: 10.1038/s41375-020-0751.
    PubMed     Text format     Abstract available


  2. SINGH S, Ahmed D, Dolatshad H, Tatwavedi D, et al
    SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.
    Leukemia. 2020 Feb 19. pii: 10.1038/s41375-020-0753.
    PubMed     Text format    


  3. HERLING CD, Cymbalista F, Gross-Ophoff-Muller C, Bahlo J, et al
    Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
    Leukemia. 2020 Feb 18. pii: 10.1038/s41375-020-0747.
    PubMed     Text format     Abstract available


  4. GODWIN CD, Laszlo GS, Wood BL, Correnti CE, et al
    The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.
    Leukemia. 2020 Feb 18. pii: 10.1038/s41375-020-0755.
    PubMed     Text format    


  5. WANDLER AM, Huang BJ, Craig JW, Hayes K, et al
    Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.
    Leukemia. 2020 Feb 17. pii: 10.1038/s41375-020-0748.
    PubMed     Text format     Abstract available


  6. AL HINAI ASA, Grob T, Kavelaars FG, Rijken M, et al
    Archived bone marrow smears are an excellent source for NGS-based mutation detection in acute myeloid leukemia.
    Leukemia. 2020 Feb 14. pii: 10.1038/s41375-020-0744.
    PubMed     Text format    


  7. OBERLEY MJ, Raikar SS, Wertheim GB, Malvar J, et al
    Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study.
    Leukemia. 2020 Feb 14. pii: 10.1038/s41375-020-0741.
    PubMed     Text format     Abstract available


  8. SINNAKANNU JR, Lee KL, Cheng S, Li J, et al
    SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
    Leukemia. 2020 Feb 12. pii: 10.1038/s41375-020-0732.
    PubMed     Text format     Abstract available


  9. ROY DC, Walker I, Maertens J, Lewalle P, et al
    ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.
    Leukemia. 2020 Feb 11. pii: 10.1038/s41375-020-0733.
    PubMed     Text format     Abstract available


  10. HSIEHCHEN D, Goralski M, Kim J, Xie Y, et al
    Biomarkers for RBM39 degradation in acute myeloid leukemia.
    Leukemia. 2020 Feb 10. pii: 10.1038/s41375-020-0729.
    PubMed     Text format    


  11. NADEU F, Royo R, Maura F, Dawson KJ, et al
    Minimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosis.
    Leukemia. 2020 Feb 4. pii: 10.1038/s41375-020-0730.
    PubMed     Text format    


    January 2020
  12. JACOBS S, Ausema A, Zwart E, Weersing E, et al
    Correction: Quantitative distribution of patient-derived leukemia clones in murine xenografts revealed by cellular barcodes.
    Leukemia. 2020 Jan 31. pii: 10.1038/s41375-020-0722.
    PubMed     Text format     Abstract available


  13. KINSTRIE R, Horne GA, Morrison H, Irvine D, et al
    Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
    Leukemia. 2020 Jan 31. pii: 10.1038/s41375-020-0721.
    PubMed     Text format     Abstract available


  14. HUET S, Bouvard A, Ferrant E, Mosnier I, et al
    Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia.
    Leukemia. 2020 Jan 29. pii: 10.1038/s41375-020-0716.
    PubMed     Text format    


  15. PEMOV A, Pathak A, Jones SJ, Dewan R, et al
    In search of genetic factors predisposing to familial hairy cell leukemia (HCL): exome-sequencing of four multiplex HCL pedigrees.
    Leukemia. 2020 Jan 28. pii: 10.1038/s41375-019-0702.
    PubMed     Text format    


  16. YAN B, Chen Q, Xu J, Li W, et al
    Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.
    Leukemia. 2020 Jan 27. pii: 10.1038/s41375-020-0710.
    PubMed     Text format     Abstract available


  17. GAZEAU N, Derrieux C, Nibourel O, Berthon C, et al
    Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.
    Leukemia. 2020 Jan 27. pii: 10.1038/s41375-020-0715.
    PubMed     Text format    


  18. DANYLESKO I, Jacoby E, Yerushalmi R, Shem-Tov N, et al
    Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells.
    Leukemia. 2020 Jan 24. pii: 10.1038/s41375-020-0719.
    PubMed     Text format    


  19. THAN H, Pomicter AD, Yan D, Beaver LP, et al
    Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.
    Leukemia. 2020 Jan 24. pii: 10.1038/s41375-020-0708.
    PubMed     Text format    


  20. PFEIFER H, Cazzaniga G, van der Velden VHJ, Cayuela JM, et al
    Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Leukemia. 2020 Jan 14. pii: 10.1038/s41375-020-0707.
    PubMed     Text format     Abstract available


  21. ANTAR AI, Otrock ZK, Jabbour E, Mohty M, et al
    FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Leukemia. 2020 Jan 9. pii: 10.1038/s41375-019-0694.
    PubMed     Text format     Abstract available


  22. VERMA D, Zanetti C, Godavarthy PS, Kumar R, et al
    Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia.
    Leukemia. 2020 Jan 9. pii: 10.1038/s41375-019-0674.
    PubMed     Text format     Abstract available


  23. ESTEY E, Karp JE, Emadi A, Othus M, et al
    Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Leukemia. 2020 Jan 8. pii: 10.1038/s41375-019-0704.
    PubMed     Text format     Abstract available


  24. HE H, Kondo Y, Ishiyama K, Alatrash G, et al
    Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.
    Leukemia. 2020 Jan 6. pii: 10.1038/s41375-019-0698.
    PubMed     Text format     Abstract available


  25. OPATZ S, Bamopoulos SA, Metzeler KH, Herold T, et al
    The clinical mutatome of core binding factor leukemia.
    Leukemia. 2020 Jan 2. pii: 10.1038/s41375-019-0697.
    PubMed     Text format     Abstract available


  26. KINSTRIE R, Horne GA, Morrison H, Irvine D, et al
    CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
    Leukemia. 2020 Jan 2. pii: 10.1038/s41375-019-0684.
    PubMed     Text format     Abstract available


    December 2019
  27. KIM E, Ten Hacken E, Sivina M, Clarke A, et al
    The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
    Leukemia. 2019 Dec 20. pii: 10.1038/s41375-019-0682.
    PubMed     Text format     Abstract available


  28. JACOBS S, Ausema A, Zwart E, Weersing E, et al
    Quantitative distribution of patient-derived leukemia clones in murine xenografts revealed by cellular barcodes.
    Leukemia. 2019 Dec 18. pii: 10.1038/s41375-019-0695.
    PubMed     Text format    


  29. SOMERS K, Evans K, Cheung L, Karsa M, et al
    Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.
    Leukemia. 2019 Dec 17. pii: 10.1038/s41375-019-0683.
    PubMed     Text format     Abstract available


  30. STONER RC, Press RD, Maxson JE, Tyner JW, et al
    Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.
    Leukemia. 2019 Dec 16. pii: 10.1038/s41375-019-0688.
    PubMed     Text format    


  31. COLTRO G, Mangaonkar AA, Lasho TL, Finke CM, et al
    Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Leukemia. 2019 Dec 13. pii: 10.1038/s41375-019-0690.
    PubMed     Text format     Abstract available


  32. ARRUGA F, Bracciama V, Vitale N, Vaisitti T, et al
    Correction: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
    Leukemia. 2019 Dec 13. pii: 10.1038/s41375-019-0680.
    PubMed     Text format     Abstract available


  33. ERNST T, Rinke J, Hagen J, Dmytrenko I, et al
    Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disaster.
    Leukemia. 2019 Dec 13. pii: 10.1038/s41375-019-0679.
    PubMed     Text format    


  34. YU S, Huang F, Wang Y, Xu Y, et al
    Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study.
    Leukemia. 2019 Dec 12. pii: 10.1038/s41375-019-0686.
    PubMed     Text format     Abstract available


  35. WANG AJ, Han Y, Jia N, Chen P, et al
    NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia.
    Leukemia. 2019 Dec 12. pii: 10.1038/s41375-019-0681.
    PubMed     Text format     Abstract available


  36. MODVIG S, Madsen HO, Siitonen SM, Rosthoj S, et al
    Correction: Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Dec 10. pii: 10.1038/s41375-019-0672.
    PubMed     Text format     Abstract available


  37. ATTARBASCHI A, Mann G, Zimmermann M, Bader P, et al
    Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.
    Leukemia. 2019 Dec 5. pii: 10.1038/s41375-019-0670.
    PubMed     Text format    


  38. DESAI R, Taghavi S, Chase JC, Chopra M, et al
    Unexpected variation in leukemia stem cell frequency and genetic heterogeneity in two murine leukemia models initiated by AML1/ETO9a and CALM/AF10.
    Leukemia. 2019 Dec 4. pii: 10.1038/s41375-019-0657.
    PubMed     Text format    


  39. MORSINK LM, Bezerra ED, Othus M, Wood BL, et al
    Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease.
    Leukemia. 2019 Dec 3. pii: 10.1038/s41375-019-0671.
    PubMed     Text format    


    November 2019
  40. ELCHEVA IA, Wood T, Chiarolanzio K, Chim B, et al
    RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1.
    Leukemia. 2019 Nov 25. pii: 10.1038/s41375-019-0656.
    PubMed     Text format     Abstract available


  41. PAGANI IS, Dang P, Saunders VA, Grose R, et al
    Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
    Leukemia. 2019 Nov 25. pii: 10.1038/s41375-019-0647.
    PubMed     Text format     Abstract available


  42. BOUVIER A, Riou J, Thepot S, Sutra Del Galy A, et al
    Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.
    Leukemia. 2019 Nov 25. pii: 10.1038/s41375-019-0624.
    PubMed     Text format     Abstract available


  43. SAUER MG, Lang PJ, Albert MH, Bader P, et al
    Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.
    Leukemia. 2019 Nov 25. pii: 10.1038/s41375-019-0648.
    PubMed     Text format     Abstract available


  44. QUINTARELLI C, Sivori S, Caruso S, Carlomagno S, et al
    Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2019 Nov 19. pii: 10.1038/s41375-019-0613.
    PubMed     Text format     Abstract available


  45. BARILA G, Teramo A, Calabretto G, Vicenzetto C, et al
    Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients.
    Leukemia. 2019 Nov 18. pii: 10.1038/s41375-019-0644.
    PubMed     Text format     Abstract available


  46. LIEBERS N, Roider T, Bohn JP, Haberbosch I, et al
    BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials.
    Leukemia. 2019 Nov 18. pii: 10.1038/s41375-019-0646.
    PubMed     Text format    


  47. KIMURA S, Seki M, Kawai T, Goto H, et al
    DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes.
    Leukemia. 2019 Nov 15. pii: 10.1038/s41375-019-0626.
    PubMed     Text format    


  48. FURSTENAU M, Hopfinger G, Robrecht S, Fink AM, et al
    Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
    Leukemia. 2019 Nov 14. pii: 10.1038/s41375-019-0630.
    PubMed     Text format    


  49. HARTMANN L, Nadarajah N, Meggendorfer M, Hollein A, et al
    Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.
    Leukemia. 2019 Nov 12. pii: 10.1038/s41375-019-0633.
    PubMed     Text format     Abstract available


  50. BUENO-COSTA A, Pineyro D, Soler M, Javierre BM, et al
    B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation.
    Leukemia. 2019 Nov 12. pii: 10.1038/s41375-019-0643.
    PubMed     Text format    


  51. MOHTY M, Gautier J, Malard F, Aljurf M, et al
    CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
    Leukemia. 2019 Nov 5. pii: 10.1038/s41375-019-0615.
    PubMed     Text format     Abstract available


    October 2019
  52. TATSUMI G, Kawahara M, Imai T, Nishishita-Asai A, et al
    Thiopurine-mediated impairment of hematopoietic stem and leukemia cells in Nudt15(R138C) knock-in mice.
    Leukemia. 2019 Oct 24. pii: 10.1038/s41375-019-0583.
    PubMed     Text format     Abstract available


  53. ELSAYED AH, Rafiee R, Cao X, Raimondi S, et al
    A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
    Leukemia. 2019 Oct 23. pii: 10.1038/s41375-019-0604.
    PubMed     Text format     Abstract available


  54. KOTROVA M, Volland A, Kehden B, Trautmann H, et al
    Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia.
    Leukemia. 2019 Oct 22. pii: 10.1038/s41375-019-0599.
    PubMed     Text format    


  55. VORBACH S, Grunder A, Zhou F, Koellerer C, et al
    Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice.
    Leukemia. 2019 Oct 21. pii: 10.1038/s41375-019-0577.
    PubMed     Text format     Abstract available


  56. JONAS BA, Pollyea DA
    How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
    Leukemia. 2019 Oct 18. pii: 10.1038/s41375-019-0612.
    PubMed     Text format     Abstract available


  57. JIN X, Cao Y, Wang L, Sun R, et al
    HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
    Leukemia. 2019 Oct 18. pii: 10.1038/s41375-019-0610.
    PubMed     Text format    


  58. SAIDA S, Zhen T, Kim E, Yu K, et al
    Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
    Leukemia. 2019 Oct 17. pii: 10.1038/s41375-019-0605.
    PubMed     Text format     Abstract available


  59. DURRANI J, Awada H, Kishtagari A, Visconte V, et al
    Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome.
    Leukemia. 2019 Oct 17. pii: 10.1038/s41375-019-0601.
    PubMed     Text format    


  60. LEUNG KT, Zhang C, Chan KYY, Li K, et al
    CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity.
    Leukemia. 2019 Oct 17. pii: 10.1038/s41375-019-0593.
    PubMed     Text format     Abstract available


  61. ALANAZI B, Munje CR, Rastogi N, Williamson AJK, et al
    Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0596.
    PubMed     Text format     Abstract available


  62. FURSTENAU M, Bahlo J, Fink AM, Lange E, et al
    Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0597.
    PubMed     Text format    


  63. QUIST-PAULSEN P, Toft N, Heyman M, Abrahamsson J, et al
    T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0598.
    PubMed     Text format     Abstract available


  64. CICCONI L, Platzbecker U, Avvisati G, Paoloni F, et al
    Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0589.
    PubMed     Text format    


  65. WU Z, Sun H, Liu W, Zhu H, et al
    Circ-RPL15: a plasma circular RNA as novel oncogenic driver to promote progression of chronic lymphocytic leukemia.
    Leukemia. 2019 Oct 14. pii: 10.1038/s41375-019-0594.
    PubMed     Text format    


  66. BACCARANI M, Iacobucci I, Chiaretti S, Foa' R, et al
    In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent.
    Leukemia. 2019 Oct 8. pii: 10.1038/s41375-019-0591.
    PubMed     Text format    


  67. TUMINO N, Besi F, Di Pace AL, Mariotti FR, et al
    PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation.
    Leukemia. 2019 Oct 4. pii: 10.1038/s41375-019-0585.
    PubMed     Text format    


  68. HALPERN AB, Howard NP, Othus M, Hendrie PC, et al
    Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.
    Leukemia. 2019 Oct 4. pii: 10.1038/s41375-019-0586.
    PubMed     Text format    


  69. SAUER MG, Lang PJ, Albert MH, Bader P, et al
    Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.
    Leukemia. 2019 Oct 2. pii: 10.1038/s41375-019-0584.
    PubMed     Text format     Abstract available


  70. MEYER T, Jahn N, Lindner S, Rohner L, et al
    Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).
    Leukemia. 2019 Oct 1. pii: 10.1038/s41375-019-0578.
    PubMed     Text format     Abstract available


  71. KARJALAINEN R, Liu M, Kumar A, He L, et al
    Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
    Leukemia. 2019;33:2548-2553.
    PubMed     Text format    


  72. BLATTE TJ, Schmalbrock LK, Skambraks S, Lux S, et al
    getITD for FLT3-ITD-based MRD monitoring in AML.
    Leukemia. 2019;33:2535-2539.
    PubMed     Text format    


  73. CHRISTIAN S, Merz C, Evans L, Gradl S, et al
    The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
    Leukemia. 2019;33:2403-2415.
    PubMed     Text format     Abstract available


  74. MALLANEY C, Ostrander EL, Celik H, Kramer AC, et al
    Kdm6b regulates context-dependent hematopoietic stem cell self-renewal and leukemogenesis.
    Leukemia. 2019;33:2506-2521.
    PubMed     Text format     Abstract available


    September 2019
  75. THASTRUP M, Marquart HV, Levinsen M, Grell K, et al
    Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.
    Leukemia. 2019 Sep 18. pii: 10.1038/s41375-019-0570.
    PubMed     Text format     Abstract available


  76. AZADNIV M, Myers JR, McMurray HR, Guo N, et al
    Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support.
    Leukemia. 2019 Sep 6. pii: 10.1038/s41375-019-0568.
    PubMed     Text format     Abstract available


  77. ZHANG Z, Li L, Wu C, Yin G, et al
    Inhibition of Slug effectively targets leukemia stem cells via the Slc13a3/ROS signaling pathway.
    Leukemia. 2019 Sep 6. pii: 10.1038/s41375-019-0566.
    PubMed     Text format     Abstract available


  78. EFFICACE F, Stagno F, Iurlo A, Breccia M, et al
    Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
    Leukemia. 2019 Sep 2. pii: 10.1038/s41375-019-0563.
    PubMed     Text format     Abstract available


  79. BRUGGEMANN M, Kotrova M, Knecht H, Bartram J, et al
    Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
    Leukemia. 2019;33:2241-2253.
    PubMed     Text format     Abstract available


  80. MEYER C, Lopes BA, Caye-Eude A, Cave H, et al
    Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions.
    Leukemia. 2019;33:2306-2340.
    PubMed     Text format    


    August 2019
  81. ARRUGA F, Bracciama V, Vitale N, Vaisitti T, et al
    Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
    Leukemia. 2019 Aug 29. pii: 10.1038/s41375-019-0571.
    PubMed     Text format     Abstract available


  82. ENYA CHEN YC, Burgess M, Mapp S, Mollee P, et al
    PI3K-p110delta contributes to antibody responses by macrophages in chronic lymphocytic leukemia.
    Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0556.
    PubMed     Text format     Abstract available


  83. AGRAWAL M, Schwarz P, Giaimo BD, Bedzhov I, et al
    Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
    Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0551.
    PubMed     Text format    


  84. SMITH LD, Minton AR, Blunt MD, Karydis LI, et al
    BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia.
    Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0557.
    PubMed     Text format    


  85. BHATNAGAR B, Eisfeld AK, Kohlschmidt J, Mrozek K, et al
    Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.
    Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0560.
    PubMed     Text format     Abstract available


  86. BACCARANI M, Rosti G, Soverini S
    Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.
    Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0562.
    PubMed     Text format     Abstract available


  87. BOSCH F, Cantin G, Cortelezzi A, Knauf W, et al
    Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.
    Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0554.
    PubMed     Text format     Abstract available


  88. WEISBERG E, Meng C, Case A, Sattler M, et al
    Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
    Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0552.
    PubMed     Text format    


  89. CAZZOLA A, Schlegel C, Jansen I, Bochtler T, et al
    TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.
    Leukemia. 2019 Aug 23. pii: 10.1038/s41375-019-0550.
    PubMed     Text format     Abstract available


  90. HIXON JA, Andrews C, Kashi L, Kohnhorst CL, et al
    New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.
    Leukemia. 2019 Aug 22. pii: 10.1038/s41375-019-0531.
    PubMed     Text format     Abstract available


  91. KIM JC, Zuzarte PC, Murphy T, Chan-Seng-Yue M, et al
    Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencing.
    Leukemia. 2019 Aug 21. pii: 10.1038/s41375-019-0546.
    PubMed     Text format    


  92. OFRAN Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, et al
    Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.
    Leukemia. 2019 Aug 21. pii: 10.1038/s41375-019-0548.
    PubMed     Text format    


  93. AWADA H, Rahman S, Durrani J, Asad MF, et al
    Leukemia evolving from paroxysmal nocturnal hemoglobinuria.
    Leukemia. 2019 Aug 20. pii: 10.1038/s41375-019-0555.
    PubMed     Text format    


  94. KREUZER KA, Furman RR, Stilgenbauer S, Dubowy RL, et al
    The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
    Leukemia. 2019 Aug 19. pii: 10.1038/s41375-019-0533.
    PubMed     Text format    


  95. SHEM-TOV N, Peczynski C, Labopin M, Itala-Remes M, et al
    Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT.
    Leukemia. 2019 Aug 19. pii: 10.1038/s41375-019-0544.
    PubMed     Text format     Abstract available


  96. KUEPPER MK, Butow M, Herrmann O, Ziemons J, et al
    Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.
    Leukemia. 2019;33:1964-1977.
    PubMed     Text format     Abstract available


  97. SINCLAIR PB, Ryan S, Bashton M, Hollern S, et al
    SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain.
    Leukemia. 2019;33:1881-1894.
    PubMed     Text format     Abstract available


  98. ESCUDERO L, Cleal K, Ashelford K, Fegan C, et al
    Telomere fusions associate with coding sequence and copy number alterations in CLL.
    Leukemia. 2019;33:2093-2097.
    PubMed     Text format    


  99. SCHLENK RF, Weber D, Herr W, Wulf G, et al
    Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.
    Leukemia. 2019;33:1923-1933.
    PubMed     Text format     Abstract available


  100. YASSIN M, Aqaqe N, Yassin AA, van Galen P, et al
    A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity.
    Leukemia. 2019;33:2061-2077.
    PubMed     Text format     Abstract available


  101. NORRIS K, Hillmen P, Rawstron A, Hills R, et al
    Telomere length predicts for outcome to FCR chemotherapy in CLL.
    Leukemia. 2019;33:1953-1963.
    PubMed     Text format     Abstract available


  102. SHIELDS BJ, Slape CI, Vo N, Jackson JT, et al
    The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.
    Leukemia. 2019;33:1868-1880.
    PubMed     Text format     Abstract available


  103. RACK KA, van den Berg E, Haferlach C, Beverloo HB, et al
    European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.
    Leukemia. 2019;33:1851-1867.
    PubMed     Text format     Abstract available


    July 2019
  104. WANG S, Ge M, Cui J, Qiao Z, et al
    Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia.
    Leukemia. 2019 Jul 24. pii: 10.1038/s41375-019-0526.
    PubMed     Text format    


  105. ADVANI PG, Schonfeld SJ, Curtis RE, Dores GM, et al
    Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study.
    Leukemia. 2019 Jul 24. pii: 10.1038/s41375-019-0520.
    PubMed     Text format    


  106. WANG H, Zhao D, Nguyen LX, Wu H, et al
    Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
    Leukemia. 2019 Jul 23. pii: 10.1038/s41375-019-0522.
    PubMed     Text format     Abstract available


  107. CAO J, Cheng H, Shi M, Wang G, et al
    Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Jul 15. pii: 10.1038/s41375-019-0516.
    PubMed     Text format    


  108. DE SMITH AJ, Walsh KM, Morimoto LM, Francis SS, et al
    Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome.
    Leukemia. 2019 Jul 11. pii: 10.1038/s41375-019-0514.
    PubMed     Text format    


  109. ZHANG MM, Liu N, Zhang YL, Rong B, et al
    Destabilization of AETFC through C/EBPalpha-mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation.
    Leukemia. 2019;33:1822-1827.
    PubMed     Text format    


  110. SPORTOLETTI P, Celani L, Varasano E, Rossi R, et al
    GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations.
    Leukemia. 2019;33:1827-1832.
    PubMed     Text format    


  111. LOBERG MA, Bell RK, Goodwin LO, Eudy E, et al
    Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
    Leukemia. 2019;33:1635-1649.
    PubMed     Text format     Abstract available


  112. HOHTARI H, Bruck O, Blom S, Turkki R, et al
    Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL.
    Leukemia. 2019;33:1570-1582.
    PubMed     Text format     Abstract available


    June 2019
  113. BRANFORD S, Kim DDH, Apperley JF, Eide CA, et al
    Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
    Leukemia. 2019 Jun 17. pii: 10.1038/s41375-019-0512.
    PubMed     Text format     Abstract available


  114. STIEF SM, Hanneforth AL, Weser S, Mattes R, et al
    Loss of KDM6A confers drug resistance in acute myeloid leukemia.
    Leukemia. 2019 Jun 14. pii: 10.1038/s41375-019-0497.
    PubMed     Text format     Abstract available


  115. GIMENEZ N, Schulz R, Higashi M, Aymerich M, et al
    Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
    Leukemia. 2019 Jun 13. pii: 10.1038/s41375-019-0507.
    PubMed     Text format     Abstract available


  116. ANGENENDT L, Bormann E, Pabst C, Alla V, et al
    The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
    Leukemia. 2019 Jun 10. pii: 10.1038/s41375-019-0505.
    PubMed     Text format     Abstract available


  117. BARTH J, Abou-El-Ardat K, Dalic D, Kurrle N, et al
    LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Leukemia. 2019;33:1411-1426.
    PubMed     Text format     Abstract available


  118. LYNCH JR, Salik B, Connerty P, Vick B, et al
    JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
    Leukemia. 2019;33:1400-1410.
    PubMed     Text format     Abstract available


  119. DUBOIS A, Furstoss N, Calleja A, Zerhouni M, et al
    LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.
    Leukemia. 2019;33:1501-1513.
    PubMed     Text format     Abstract available


  120. SAENZ DT, Fiskus W, Manshouri T, Mill CP, et al
    Targeting nuclear beta-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
    Leukemia. 2019;33:1373-1386.
    PubMed     Text format     Abstract available


    May 2019
  121. TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
    Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.
    Leukemia. 2019 May 30. pii: 10.1038/s41375-019-0494.
    PubMed     Text format     Abstract available


  122. ARMENTEROS-MONTERROSO E, Zhao L, Gasparoli L, Brooks T, et al
    The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
    Leukemia. 2019 May 28. pii: 10.1038/s41375-019-0495.
    PubMed     Text format     Abstract available


  123. NII T, Prabhu VV, Ruvolo V, Madhukar N, et al
    Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
    Leukemia. 2019 May 24. pii: 10.1038/s41375-019-0491.
    PubMed     Text format     Abstract available


  124. HOUSHMAND M, Simonetti G, Circosta P, Gaidano V, et al
    Chronic myeloid leukemia stem cells.
    Leukemia. 2019 May 24. pii: 10.1038/s41375-019-0490.
    PubMed     Text format     Abstract available


  125. PAN J, Niu Q, Deng B, Liu S, et al
    CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
    Leukemia. 2019 May 20. pii: 10.1038/s41375-019-0488.
    PubMed     Text format     Abstract available


  126. STILGENBAUER S, Aurran Schleinitz T, Eichhorst B, Lang F, et al
    Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
    Leukemia. 2019 May 14. pii: 10.1038/s41375-019-0475.
    PubMed     Text format    


  127. USTUN C, Le-Rademacher J, Wang HL, Othus M, et al
    Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
    Leukemia. 2019 May 9. pii: 10.1038/s41375-019-0477.
    PubMed     Text format     Abstract available


  128. BATALLER A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G, et al
    The role of TGFbeta in hematopoiesis and myeloid disorders.
    Leukemia. 2019;33:1076-1089.
    PubMed     Text format     Abstract available


  129. POTTER N, Miraki-Moud F, Ermini L, Titley I, et al
    Single cell analysis of clonal architecture in acute myeloid leukaemia.
    Leukemia. 2019;33:1113-1123.
    PubMed     Text format     Abstract available


  130. WANG TT, Yang J, Zhang Y, Zhang M, et al
    IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective gamma-chain cytokines, decreases leukemic T-cell viability.
    Leukemia. 2019;33:1243-1255.
    PubMed     Text format     Abstract available


  131. PAGANO MA, Tibaldi E, Molino P, Frezzato F, et al
    Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.
    Leukemia. 2019;33:1148-1160.
    PubMed     Text format     Abstract available


    April 2019
  132. POLLYEA DA, Tallman MS, de Botton S, Kantarjian HM, et al
    Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0472.
    PubMed     Text format     Abstract available


  133. DONG Y, Zhao X, Feng X, Zhou Y, et al
    SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0456.
    PubMed     Text format     Abstract available


  134. KLEIN K, Witalisz-Siepracka A, Maurer B, Prinz D, et al
    STAT5B(N642H) drives transformation of NKT cells: a novel mouse model for CD56(+) T-LGL leukemia.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0471.
    PubMed     Text format    


  135. LIN M, Nebral K, Gertzen CGW, Ganmore I, et al
    JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility.
    Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0459.
    PubMed     Text format    


  136. HYRENIUS-WITTSTEN A, Pilheden M, Falques-Costa A, Eriksson M, et al
    FLT3(N676K) drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0465.
    PubMed     Text format    


  137. EISENWORT G, Sadovnik I, Schwaab J, Jawhar M, et al
    Identification of a leukemia-initiating stem cell in human mast cell leukemia.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0460.
    PubMed     Text format     Abstract available


  138. TIAN XP, Huang WJ, Huang HQ, Liu YH, et al
    Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0466.
    PubMed     Text format     Abstract available


  139. CHEN YL, Tang C, Zhang MY, Huang WL, et al
    Blocking ATM-dependent NF-kappaB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia.
    Leukemia. 2019 Apr 2. pii: 10.1038/s41375-019-0458.
    PubMed     Text format     Abstract available


  140. FALINI B, Spinelli O, Meggendorfer M, Martelli MP, et al
    IDH1-R132 changes vary according to NPM1 and other mutations status in AML.
    Leukemia. 2019;33:1043-1047.
    PubMed     Text format    


  141. POTTER N, Jones L, Blair H, Strehl S, et al
    Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.
    Leukemia. 2019;33:893-904.
    PubMed     Text format     Abstract available


  142. ZABORSKY N, Gassner FJ, Hopner JP, Schubert M, et al
    Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
    Leukemia. 2019;33:957-968.
    PubMed     Text format     Abstract available


  143. DORON B, Abdelhamed S, Butler JT, Hashmi SK, et al
    Transmissible ER stress reconfigures the AML bone marrow compartment.
    Leukemia. 2019;33:918-930.
    PubMed     Text format     Abstract available


  144. BAQUERO P, Dawson A, Mukhopadhyay A, Kuntz EM, et al
    Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
    Leukemia. 2019;33:981-994.
    PubMed     Text format     Abstract available


    March 2019
  145. EL-JAWAHRI A, Abel GA, Traeger L, Waldman L, et al
    Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
    Leukemia. 2019 Mar 28. pii: 10.1038/s41375-019-0449.
    PubMed     Text format     Abstract available


  146. JEBARAJ BMC, Tausch E, Landau DA, Bahlo J, et al
    Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.
    Leukemia. 2019 Mar 25. pii: 10.1038/s41375-019-0446.
    PubMed     Text format     Abstract available


  147. VISHWAKARMA BA, Gudmundsson KO, Oakley K, Han Y, et al
    Insertional mutagenesis identifies cooperation between Setbp1 and Mllt3 in inducing myeloid leukemia development.
    Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0445.
    PubMed     Text format    


  148. LUCAS N, Duchmann M, Rameau P, Noel F, et al
    Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.
    Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0447.
    PubMed     Text format     Abstract available


  149. RADPOUR R, Riether C, Simillion C, Hopner S, et al
    CD8(+) T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia.
    Leukemia. 2019 Mar 15. pii: 10.1038/s41375-019-0441.
    PubMed     Text format     Abstract available


  150. JANSSEN L, Frambach SJCM, Allard NAE, Hopman MTE, et al
    Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0443.
    PubMed     Text format    


  151. VENDRAMINI E, Bomben R, Pozzo F, Benedetti D, et al
    KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0444.
    PubMed     Text format    


  152. PFEIFER H, Cazzaniga G, van der Velden VHJ, Cayuela JM, et al
    Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0413.
    PubMed     Text format     Abstract available


  153. BILL M, Papaioannou D, Karunasiri M, Kohlschmidt J, et al
    Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.
    Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0429.
    PubMed     Text format     Abstract available


  154. AKKAPEDDI P, Fragoso R, Hixon JA, Ramalho AS, et al
    A fully human anti-IL-7Ralpha antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 8. pii: 10.1038/s41375-019-0434.
    PubMed     Text format     Abstract available


  155. HE X, Xiao X, Li Q, Jiang Y, et al
    Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0437.
    PubMed     Text format    


  156. CANAANI J, Labopin M, Itala-Remes M, Blaise D, et al
    Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0439.
    PubMed     Text format     Abstract available


  157. BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
    Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0426.
    PubMed     Text format     Abstract available


  158. BASTIAN L, Schroeder MP, Eckert C, Schlee C, et al
    PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 6. pii: 10.1038/s41375-019-0430.
    PubMed     Text format     Abstract available


  159. KOTANI S, Yoda A, Kon A, Kataoka K, et al
    Molecular pathogenesis of disease progression in MLL-rearranged AML.
    Leukemia. 2019;33:612-624.
    PubMed     Text format     Abstract available


  160. KONG G, You X, Wen Z, Chang YI, et al
    Downregulating Notch counteracts Kras(G12D)-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm.
    Leukemia. 2019;33:671-685.
    PubMed     Text format     Abstract available


  161. BENAJIBA L, Alexe G, Su A, Raffoux E, et al
    Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.
    Leukemia. 2019;33:800-804.
    PubMed     Text format    


  162. HUMBERT O, Laszlo GS, Sichel S, Ironside C, et al
    Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.
    Leukemia. 2019;33:762-808.
    PubMed     Text format    


    February 2019
  163. STEINHERZ PG, Seibel NL, Sather H, Ji L, et al
    Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.
    Leukemia. 2019 Feb 28. pii: 10.1038/s41375-019-0422.
    PubMed     Text format     Abstract available


  164. BUENO C, Velasco-Hernandez T, Gutierrez-Aguera F, Zanetti SR, et al
    CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.
    Leukemia. 2019 Feb 18. pii: 10.1038/s41375-019-0418.
    PubMed     Text format    


  165. MCNEER NA, Philip J, Geiger H, Ries RE, et al
    Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.
    Leukemia. 2019 Feb 13. pii: 10.1038/s41375-019-0402.
    PubMed     Text format     Abstract available


  166. MROZEK K, Eisfeld AK, Kohlschmidt J, Carroll AJ, et al
    Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.
    Leukemia. 2019 Feb 8. pii: 10.1038/s41375-019-0390.
    PubMed     Text format     Abstract available


  167. BENARD B, Gentles AJ, Kohnke T, Majeti R, et al
    Data mining for mutation-specific targets in acute myeloid leukemia.
    Leukemia. 2019 Feb 6. pii: 10.1038/s41375-019-0387.
    PubMed     Text format     Abstract available


  168. GUENOT C, Lacombe F, Allou K, Dumezy F, et al
    Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.
    Leukemia. 2019 Feb 5. pii: 10.1038/s41375-019-0393.
    PubMed     Text format    


  169. DAVER N, Schlenk RF, Russell NH, Levis MJ, et al
    Targeting FLT3 mutations in AML: review of current knowledge and evidence.
    Leukemia. 2019;33:299-312.
    PubMed     Text format     Abstract available


  170. HOURIGAN CS, Gale RP, Walter RB
    Refining AML outcome prediction.
    Leukemia. 2019;33:283-284.
    PubMed     Text format    


  171. HERNANDEZ-SANCHEZ M, Kotaskova J, Rodriguez AE, Radova L, et al
    CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase.
    Leukemia. 2019;33:518-558.
    PubMed     Text format    


  172. BORGA C, Park G, Foster C, Burroughs-Garcia J, et al
    Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis.
    Leukemia. 2019;33:333-347.
    PubMed     Text format     Abstract available


  173. CERNA K, Oppelt J, Chochola V, Musilova K, et al
    MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
    Leukemia. 2019;33:403-414.
    PubMed     Text format     Abstract available


  174. ENGEL N, Rovo A, Badoglio M, Labopin M, et al
    European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation.
    Leukemia. 2019;33:508-517.
    PubMed     Text format     Abstract available


  175. KAMPEN KR, Sulima SO, Verbelen B, Girardi T, et al
    The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
    Leukemia. 2019;33:319-332.
    PubMed     Text format     Abstract available


    January 2019
  176. MASCHMEYER G, De Greef J, Mellinghoff SC, Nosari A, et al
    Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).
    Leukemia. 2019 Jan 30. pii: 10.1038/s41375-019-0388.
    PubMed     Text format     Abstract available


  177. CHEN R, Zhu M, Chaudhari RR, Robles O, et al
    Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
    Leukemia. 2019 Jan 30. pii: 10.1038/s41375-018-0364.
    PubMed     Text format     Abstract available


  178. SHI Y, Wang G, Muhowski EM, McCaw L, et al
    Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
    Leukemia. 2019 Jan 29. pii: 10.1038/s41375-019-0381.
    PubMed     Text format     Abstract available


  179. SCHMIDT L, Heyes E, Scheiblecker L, Eder T, et al
    CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-019-0382.
    PubMed     Text format     Abstract available


  180. KROMBHOLZ CF, Gallego-Villar L, Sahoo SS, Panda PK, et al
    Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0343.
    PubMed     Text format    


  181. MOYSIADIS T, Baliakas P, Rossi D, Catherwood M, et al
    Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen b-receptors.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0322.
    PubMed     Text format    


  182. KOLLMANN S, Grundschober E, Maurer B, Warsch W, et al
    Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
    Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0369.
    PubMed     Text format     Abstract available


  183. HOFFMANN H, Thiede C, Glauche I, Kramer M, et al
    The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0371.
    PubMed     Text format    


  184. NABINGER SC, Chen S, Gao R, Yao C, et al
    Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-019-0377.
    PubMed     Text format    


  185. BACCARANI M, Castagnetti F, Gugliotta G, Rosti G, et al
    The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.
    Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0341.
    PubMed     Text format     Abstract available


  186. ESTEY E, Othus M, Gale RP
    New study-designs to address the clinical complexity of acute myeloid leukemia.
    Leukemia. 2019 Jan 22. pii: 10.1038/s41375-018-0363.
    PubMed     Text format    


  187. FIORCARI S, Benatti S, Zucchetto A, Zucchini P, et al
    Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS.
    Leukemia. 2019 Jan 18. pii: 10.1038/s41375-018-0296.
    PubMed     Text format    


  188. ALFONSO V, Iaccarino L, Ottone T, Cicconi L, et al
    Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
    Leukemia. 2019 Jan 16. pii: 10.1038/s41375-018-0298.
    PubMed     Text format    


  189. LOPEZ-MILLAN B, Sanchez-Martinez D, Roca-Ho H, Gutierrez-Aguera F, et al
    NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0353.
    PubMed     Text format     Abstract available


  190. JAWHAR M, Dohner K, Kreil S, Schwaab J, et al
    KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0346.
    PubMed     Text format     Abstract available


  191. REDA G, Cassin R, Gentile M, Mauro FR, et al
    IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0344.
    PubMed     Text format    


  192. OZTURK S, Roessner PM, Schulze-Edinghausen L, Yazdanparast H, et al
    Rejection of adoptively transferred Emicro-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0332.
    PubMed     Text format    


  193. HOANG VT, Verma D, Godavarthy PS, Llavona P, et al
    The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
    Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0358.
    PubMed     Text format     Abstract available


  194. GOUNARI M, Ntoufa S, Gerousi M, Vilia MG, et al
    Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
    Leukemia. 2019 Jan 3. pii: 10.1038/s41375-018-0335.
    PubMed     Text format    


  195. NIYONGERE S, Lucas N, Zhou JM, Sansil S, et al
    Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.
    Leukemia. 2019;33:205-216.
    PubMed     Text format     Abstract available


  196. DWIVEDI P, Muench DE, Wagner M, Azam M, et al
    Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.
    Leukemia. 2019;33:75-87.
    PubMed     Text format     Abstract available


  197. HAUBNER S, Perna F, Kohnke T, Schmidt C, et al
    Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
    Leukemia. 2019;33:64-74.
    PubMed     Text format     Abstract available


  198. ARAKI M, Yang Y, Imai M, Mizukami Y, et al
    Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
    Leukemia. 2019;33:122-131.
    PubMed     Text format     Abstract available


  199. SCHNEIDT V, Ilecka M, Dreger P, van Zyl DG, et al
    Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo.
    Leukemia. 2019;33:88-98.
    PubMed     Text format     Abstract available


  200. FRASZCZAK J, Vadnais C, Rashkovan M, Ross J, et al
    Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice.
    Leukemia. 2019;33:110-121.
    PubMed     Text format     Abstract available


  201. SHIMONI A, Labopin M, Lorentino F, Van Lint MT, et al
    Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
    Leukemia. 2019;33:230-239.
    PubMed     Text format     Abstract available


    December 2018
  202. ZHAO J, Liang JW, Xue HL, Shen SH, et al
    The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
    Leukemia. 2018 Dec 21. pii: 10.1038/s41375-018-0338.
    PubMed     Text format     Abstract available


  203. VELAZQUEZ-AVILA M, Balandran JC, Ramirez-Ramirez D, Velazquez-Avila M, et al
    High cortactin expression in B-cell acute lymphoblastic leukemia is associated with increased transendothelial migration and bone marrow relapse.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0333.
    PubMed     Text format     Abstract available


  204. SCHETELIG J, de Wreede LC, van Gelder M, Koster L, et al
    Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0302.
    PubMed     Text format     Abstract available


  205. EFFICACE F, Breccia M, Avvisati G, Cottone F, et al
    Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0325.
    PubMed     Text format     Abstract available


  206. BORGA C, Foster CA, Iyer S, Garcia SP, et al
    Molecularly distinct models of zebrafish Myc-induced B cell leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0328.
    PubMed     Text format    


  207. HANNA BS, Roessner PM, Scheffold A, Jebaraj BMC, et al
    PI3Kdelta inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0318.
    PubMed     Text format     Abstract available


  208. VON TRESCKOW J, Cramer P, Bahlo J, Robrecht S, et al
    CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0313.
    PubMed     Text format     Abstract available


  209. KIVIOJA JL, Thanasopoulou A, Kumar A, Kontro M, et al
    Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0327.
    PubMed     Text format     Abstract available


  210. REEDIJK AMJ, Klein K, Coebergh JWW, Kremer LC, et al
    Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0314.
    PubMed     Text format     Abstract available


  211. HASAN MK, Rassenti L, Widhopf GF 2nd, Yu J, et al
    Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0306.
    PubMed     Text format     Abstract available


  212. CORTES JE, Heidel FH, Hellmann A, Fiedler W, et al
    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0312.
    PubMed     Text format     Abstract available


  213. PARK JH, Woo YM, Youm EM, Hamad N, et al
    HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0321.
    PubMed     Text format     Abstract available


  214. TEN HACKEN E, Gounari M, Ghia P, Burger JA, et al
    The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0303.
    PubMed     Text format     Abstract available


  215. MODVIG S, Madsen HO, Siitonen SM, Rosthoj S, et al
    Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 14. pii: 10.1038/s41375-018-0307.
    PubMed     Text format     Abstract available


  216. SCHERR M, Kirchhoff H, Battmer K, Wohlan K, et al
    Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0315.
    PubMed     Text format     Abstract available


  217. ANDERSEN MA, Moser CE, Lundgren J, Niemann CU, et al
    Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0316.
    PubMed     Text format     Abstract available


  218. ZEIJLEMAKER W, Grob T, Meijer R, Hanekamp D, et al
    CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
    Leukemia. 2018 Dec 12. pii: 10.1038/s41375-018-0326.
    PubMed     Text format     Abstract available


  219. HU X, Xu S, Chen Y, Gao Z, et al
    Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis.
    Leukemia. 2018 Dec 5. pii: 10.1038/s41375-018-0301.
    PubMed     Text format     Abstract available


    November 2018
  220. BLAGITKO-DORFS N, Schlosser P, Greve G, Pfeifer D, et al
    Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
    Leukemia. 2018 Nov 23. pii: 10.1038/s41375-018-0293.
    PubMed     Text format     Abstract available


    October 2018
  221. CAESER R, Collord G, Yao WQ, Chen Z, et al
    Targeting MEK in vemurafenib-resistant hairy cell leukemia.
    Leukemia. 2018 Oct 19. pii: 10.1038/s41375-018-0270.
    PubMed     Text format    


  222. KRAFT B, Lombard J, Kirsch M, Wuchter P, et al
    SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia.
    Leukemia. 2018 Oct 15. pii: 10.1038/s41375-018-0287.
    PubMed     Text format    


  223. FRASER G, Cramer P, Demirkan F, Silva RS, et al
    Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
    PubMed     Text format     Abstract available


  224. OTHUS M, Sekeres MA, Nand S, Garcia-Manero G, et al
    Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0275.
    PubMed     Text format     Abstract available


  225. OTHUS M, Estey EH, Garcia-Manero G, Wood BL, et al
    Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0274.
    PubMed     Text format    


  226. ROSS DM, Pagani IS, Shanmuganathan N, Kok CH, et al
    Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0264.
    PubMed     Text format     Abstract available


  227. MANSO BA, Zhang H, Mikkelson MG, Gwin KA, et al
    Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0280.
    PubMed     Text format     Abstract available


  228. YAN B, Chen Q, Shimada K, Tang M, et al
    Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0279.
    PubMed     Text format     Abstract available


  229. WALKER CJ, Oakes CC, Genutis LK, Giacopelli B, et al
    Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0281.
    PubMed     Text format    


  230. BRAESS J, Amler S, Kreuzer KA, Spiekermann K, et al
    Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0268.
    PubMed     Text format     Abstract available


  231. DOHNER H, Dolnik A, Tang L, Seymour JF, et al
    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0257.
    PubMed     Text format     Abstract available


  232. VANDEPOELE K, Van der Meulen J, Denys B
    The NF1 hotspot in acute myeloid leukemia: what's in a name?
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0266.
    PubMed     Text format    


    September 2018
  233. BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
    Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0265.
    PubMed     Text format     Abstract available


  234. HANNA BS, Roessner PM, Yazdanparast H, Colomer D, et al
    Control of chronic lymphocytic leukemia development by clonally-expanded CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues.
    Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0250.
    PubMed     Text format     Abstract available


  235. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
    Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0237.
    PubMed     Text format     Abstract available


  236. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
    Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0241.
    PubMed     Text format     Abstract available


  237. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2018 Sep 14. pii: 10.1038/s41375-018-0236.
    PubMed     Text format     Abstract available


  238. KLUPSCH K, Baeriswyl V, Scholz R, Dannenberg J, et al
    COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
    Leukemia. 2018 Sep 11. pii: 10.1038/s41375-018-0249.
    PubMed     Text format    


  239. MOUJALLED DM, Pomilio G, Ghiurau C, Ivey A, et al
    Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0261.
    PubMed     Text format     Abstract available


  240. AGHEL N, Delgado DH, Lipton JH
    Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
    Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0247.
    PubMed     Text format     Abstract available


    August 2018
  241. TAKESHITA A, Asou N, Atsuta Y, Sakura T, et al
    Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.
    Leukemia. 2018 Aug 9. pii: 10.1038/s41375-018-0233.
    PubMed     Text format     Abstract available


  242. DUPLOYEZ N, Marceau-Renaut A, Villenet C, Petit A, et al
    The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Leukemia. 2018 Aug 8. pii: 10.1038/s41375-018-0227.
    PubMed     Text format     Abstract available


  243. PATNAIK MM, Tefferi A, Garcia-Manero G
    Blast-phase chronic myelomonocytic leukemia: more than just semantics.
    Leukemia. 2018 Aug 7. pii: 10.1038/s41375-018-0228.
    PubMed     Text format    


  244. KURTZ SE, Eide CA, Kaempf A, Mori M, et al
    Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.
    Leukemia. 2018 Aug 6. pii: 10.1038/s41375-018-0225.
    PubMed     Text format    


    July 2018
  245. LEEKSMA AC, Taylor J, Wu B, Gardner JR, et al
    Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
    Leukemia. 2018 Jul 23. pii: 10.1038/s41375-018-0215.
    PubMed     Text format     Abstract available


  246. KREITMAN RJ, Dearden C, Zinzani PL, Delgado J, et al
    Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
    Leukemia. 2018 Jul 20. pii: 10.1038/s41375-018-0210.
    PubMed     Text format     Abstract available


  247. ALDOSS I, Capelletti M, Park J, Pistofidis RS, et al
    Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.
    Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0213.
    PubMed     Text format     Abstract available


  248. CICCONI L, Fenaux P, Kantarjian H, Tallman M, et al
    Molecular remission as a therapeutic objective in acute promyelocytic leukemia.
    Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0219.
    PubMed     Text format     Abstract available


  249. LI Z, He S, Look AT
    The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
    Leukemia. 2018 Jul 15. pii: 10.1038/s41375-018-0201.
    PubMed     Text format    


  250. L'ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2018 Jul 9. pii: 10.1038/s41375-018-0177.
    PubMed     Text format     Abstract available


  251. STUDD JB, Yang M, Li Z, Vijayakrishnan J, et al
    Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism.
    Leukemia. 2018 Jul 6. pii: 10.1038/s41375-018-0184.
    PubMed     Text format     Abstract available


  252. LUNDIN-STROM KB, Biloglav A, Lilljebjorn H, Rissler M, et al
    Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Jul 2. pii: 10.1038/s41375-018-0191.
    PubMed     Text format    


    June 2018
  253. VICENTE-DUENAS C, Gonzalez-Herrero I, Sehgal L, Garcia-Ramirez I, et al
    Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia.
    Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0192.
    PubMed     Text format    


  254. MARGOLSKEE E
    So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology.
    Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0186.
    PubMed     Text format    


  255. BOND J, Labis E, Marceau-Renaut A, Duployez N, et al
    Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.
    Leukemia. 2018 Jun 27. pii: 10.1038/s41375-018-0187.
    PubMed     Text format    


  256. HOLMQVIST AS, Chen Y, Wu J, Kung M, et al
    Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.
    Leukemia. 2018 Jun 26. pii: 10.1038/s41375-018-0171.
    PubMed     Text format    


  257. CRIADO I, Blanco E, Rodriguez-Caballero A, Alcoceba M, et al
    Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.
    Leukemia. 2018 Jun 21. pii: 10.1038/s41375-018-0164.
    PubMed     Text format    


  258. SUTTORP M, Schulze P, Glauche I, Gohring G, et al
    Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0179.
    PubMed     Text format     Abstract available


  259. GEBHARD C, Glatz D, Schwarzfischer L, Wimmer J, et al
    Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0165.
    PubMed     Text format     Abstract available


  260. ERNST T, Busch M, Rinke J, Ernst J, et al
    Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.
    Leukemia. 2018 Jun 13. pii: 10.1038/s41375-018-0157.
    PubMed     Text format    


  261. BODDU P, Gurguis C, Sanford D, Cortes J, et al
    Response kinetics and factors predicting survival in core-binding factor leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0158.
    PubMed     Text format    


  262. BOUDREAUX SP, Duren RP, Call SG, Nguyen L, et al
    Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0174.
    PubMed     Text format     Abstract available


  263. TASIAN SK, Casas JA, Posocco D, Gandre-Babbe S, et al
    Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0169.
    PubMed     Text format     Abstract available


  264. TIMILSHINA N, Breunis H, Tomlinson GA, Brandwein JM, et al
    Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0162.
    PubMed     Text format     Abstract available


  265. BARGHOUT SH, Patel PS, Wang X, Xu GW, et al
    Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0167.
    PubMed     Text format     Abstract available


  266. EISFELD AK, Kohlschmidt J, Mrozek K, Mims A, et al
    NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
    Leukemia. 2018 Jun 5. pii: 10.1038/s41375-018-0147.
    PubMed     Text format     Abstract available


  267. DONG X, Zhang W, Wu H, Huang J, et al
    Structural basis of DUX4/IGH-driven transactivation.
    Leukemia. 2018;32:1466-1476.
    PubMed     Text format     Abstract available


  268. INOUE D, Fujino T, Sheridan P, Zhang YZ, et al
    A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.
    Leukemia. 2018;32:1327-1337.
    PubMed     Text format     Abstract available


  269. VERBIEST T, Finnon R, Brown N, Cruz-Garcia L, et al
    Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis.
    Leukemia. 2018;32:1435-1444.
    PubMed     Text format     Abstract available


  270. ZHENG L, Xu L, Xu Q, Yu L, et al
    Utx loss causes myeloid transformation.
    Leukemia. 2018;32:1458-1465.
    PubMed     Text format     Abstract available


    May 2018
  271. CHEUNG LC, Tickner J, Hughes AM, Skut P, et al
    New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
    Leukemia. 2018 May 8. pii: 10.1038/s41375-018-0144.
    PubMed     Text format     Abstract available


  272. MEGGENDORFER M, Cappelli LV, Walter W, Haferlach C, et al
    IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.
    Leukemia. 2018;32:1249-1253.
    PubMed     Text format    


  273. DAVIDSSON J, Puschmann A, Tedgard U, Bryder D, et al
    SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.
    Leukemia. 2018;32:1106-1115.
    PubMed     Text format     Abstract available


  274. ZHENG W, O'Hear CE, Alli R, Basham JH, et al
    PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
    Leukemia. 2018;32:1157-1167.
    PubMed     Text format     Abstract available


  275. JETANI H, Garcia-Cadenas I, Nerreter T, Thomas S, et al
    CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib.
    Leukemia. 2018;32:1168-1179.
    PubMed     Text format     Abstract available


  276. ZAMPINI M, Tregnago C, Bisio V, Simula L, et al
    Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.
    Leukemia. 2018;32:1124-1134.
    PubMed     Text format     Abstract available


  277. WONG ACH, Rasko JEJ, Wong JJ
    We skip to work: alternative splicing in normal and malignant myelopoiesis.
    Leukemia. 2018;32:1081-1093.
    PubMed     Text format     Abstract available


  278. TEFFERI A, Mudireddy M, Mannelli F, Begna KH, et al
    Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.
    Leukemia. 2018;32:1200-1210.
    PubMed     Text format     Abstract available


    April 2018
  279. PATNAIK MM, Pierola AA, Vallapureddy R, Yalniz FF, et al
    Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0143.
    PubMed     Text format    


  280. HUITING LN, Samaha Y, Zhang GL, Roderick JE, et al
    UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0141.
    PubMed     Text format     Abstract available


  281. XIAO W, Rampal R, Zhang Y, Cimera R, et al
    JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0145.
    PubMed     Text format    


  282. KAYSER S, Schlenk RF, Platzbecker U
    Management of patients with acute promyelocytic leukemia.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0139.
    PubMed     Text format     Abstract available


  283. GARCIA EG, Iyer S, Garcia SP, Loontiens S, et al
    Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0130.
    PubMed     Text format    


  284. RENNEVILLE A, Attias P, Thomas X, Bally C, et al
    Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0137.
    PubMed     Text format    


  285. DE BIE J, Demeyer S, Alberti-Servera L, Geerdens E, et al
    Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0127.
    PubMed     Text format     Abstract available


  286. PASCHKA P, Schlenk RF, Weber D, Benner A, et al
    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0129.
    PubMed     Text format     Abstract available


  287. STUDENCKA-TURSKI M, Maubach G, Feige MH, Naumann M, et al
    Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0128.
    PubMed     Text format    


  288. WARTIOVAARA-KAUTTO U, Hirvonen EAM, Pitkanen E, Heckman C, et al
    Germline alterations in a consecutive series of acute myeloid leukemia.
    Leukemia. 2018 Apr 10. pii: 10.1038/s41375-018-0049.
    PubMed     Text format    


  289. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2018 Apr 7. pii: 10.1038/s41375-018-0032.
    PubMed     Text format    


  290. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Text format     Abstract available


  291. PATNAIK MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, et al
    A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0121.
    PubMed     Text format    


  292. PETER B, Bibi S, Eisenwort G, Wingelhofer B, et al
    Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Leukemia. 2018;32:1016-1022.
    PubMed     Text format     Abstract available


  293. MAURA F, Petljak M, Lionetti M, Cifola I, et al
    Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
    Leukemia. 2018;32:1044-1048.
    PubMed     Text format    


  294. SANARICO AG, Ronchini C, Croce A, Memmi EM, et al
    The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.
    Leukemia. 2018;32:911-919.
    PubMed     Text format     Abstract available


  295. MARSILIO S, Khiabanian H, Fabbri G, Vergani S, et al
    Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.
    Leukemia. 2018;32:1041-1044.
    PubMed     Text format    


    March 2018
  296. HOSSEINI MM, Kurtz SE, Abdelhamed S, Mahmood S, et al
    Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
    Leukemia. 2018 Mar 29. pii: 10.1038/s41375-018-0112.
    PubMed     Text format     Abstract available


  297. THAN H, Qiao Y, Huang X, Yan D, et al
    Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0050.
    PubMed     Text format    


  298. HOJJAT-FARSANGI M, Daneshmanesh AH, Khan AS, Shetye J, et al
    First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0113.
    PubMed     Text format    


  299. THI NGOC PC, Tan SH, Tan TK, Chan MM, et al
    Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0110.
    PubMed     Text format     Abstract available


  300. GHIA P, Rawstron A
    Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0109.
    PubMed     Text format     Abstract available


  301. KUCHENBAUER F, Buske C
    Revisiting thrombocytopenia in acute promyelocytic leukemia.
    Leukemia. 2018 Mar 23. pii: 10.1038/s41375-018-0105.
    PubMed     Text format    


  302. RUDAT S, Pfaus A, Cheng YY, Holtmann J, et al
    RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
    Leukemia. 2018 Mar 22. pii: 10.1038/s41375-018-0102.
    PubMed     Text format     Abstract available


  303. GENTILE M, Shanafelt TD, Reda G, Mauro FR, et al
    Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0100.
    PubMed     Text format    


  304. BURNS MA, Liao ZW, Yamagata N, Pouliot GP, et al
    Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0097.
    PubMed     Text format     Abstract available


  305. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Text format     Abstract available


  306. QIN YZ, Huang XJ, Zhu HH
    Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Leukemia. 2018 Mar 14. pii: 10.1038/s41375-018-0095.
    PubMed     Text format    


  307. GUNNARSSON R, Dilorenzo S, Lundin-Strom KB, Olsson L, et al
    Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 12. pii: 10.1038/s41375-018-0092.
    PubMed     Text format     Abstract available


  308. KELLY AD, Madzo J, Madireddi P, Kropf P, et al
    Demethylator phenotypes in acute myeloid leukemia.
    Leukemia. 2018 Mar 7. pii: 10.1038/s41375-018-0084.
    PubMed     Text format     Abstract available


  309. GERBOTH S, Frittoli E, Palamidessi A, Baltanas FC, et al
    Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
    Leukemia. 2018;32:820-827.
    PubMed     Text format     Abstract available


  310. ANDERSSON EI, Putzer S, Yadav B, Dufva O, et al
    Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
    Leukemia. 2018;32:774-787.
    PubMed     Text format     Abstract available


    February 2018
  311. TAWANA K, Drazer MW, Churpek JE
    Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0051.
    PubMed     Text format     Abstract available


  312. MARUFFI M, Sposto R, Oberley MJ, Kysh L, et al
    Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0058.
    PubMed     Text format     Abstract available


  313. SAUSSELE S, Hehlmann R, Fabarius A, Jeromin S, et al
    Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
    Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0055.
    PubMed     Text format     Abstract available


  314. ALI A, Penneroux J, Dal Bello R Jr, Masse A, et al
    Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
    Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0076.
    PubMed     Text format    


  315. PETROV JC, Wada M, Pinz KG, Yan LE, et al
    Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0075.
    PubMed     Text format     Abstract available


  316. HNIZDA A, Fabry M, Moriyama T, Pachl P, et al
    Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0073.
    PubMed     Text format     Abstract available


  317. EISFELD AK, Kohlschmidt J, Mrozek K, Blachly JS, et al
    Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0068.
    PubMed     Text format     Abstract available


  318. BICCLER JL, Ostgard LSG, Severinsen MT, Marcher CW, et al
    Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0054.
    PubMed     Text format    


  319. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
    Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0034.
    PubMed     Text format     Abstract available


  320. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
    Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0039.
    PubMed     Text format     Abstract available


  321. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
    Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0035.
    PubMed     Text format     Abstract available


  322. LAVALLEE VP, Chagraoui J, MacRae T, Marquis M, et al
    Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.
    Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0069.
    PubMed     Text format     Abstract available


  323. DAVER N, Boddu P, Garcia-Manero G, Yadav SS, et al
    Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0070.
    PubMed     Text format     Abstract available


  324. L ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0033.
    PubMed     Text format     Abstract available


  325. RASCHE M, Zimmermann M, Borschel L, Bourquin JP, et al
    Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0071.
    PubMed     Text format     Abstract available


  326. STRATI P, Ferrajoli A, Wierda WG, Jain N, et al
    Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
    Leukemia. 2018 Feb 20. pii: 10.1038/s41375-018-0059.
    PubMed     Text format    


  327. CRAMER SD, Hixon JA, Andrews C, Porter RJ, et al
    Mutant IL-7Ralpha and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.
    Leukemia. 2018 Feb 15. pii: 10.1038/s41375-017-0001.
    PubMed     Text format    


  328. SUAREZ-GONZALEZ J, Martinez-Laperche C, Martinez N, Rodriguez-Macias G, et al
    Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis.
    Leukemia. 2018 Feb 5. pii: 10.1038/s41375-018-0042.
    PubMed     Text format    


  329. PENG D, Wang H, Li L, Ma X, et al
    miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0015.
    PubMed     Text format     Abstract available


  330. LA STARZA R, Messina M, Gianfelici V, Pierini V, et al
    High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0031.
    PubMed     Text format    


  331. WINGELHOFER B, Maurer B, Heyes EC, Cumaraswamy AA, et al
    Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0005.
    PubMed     Text format     Abstract available


  332. MALCIKOVA J, Tausch E, Rossi D, Sutton LA, et al
    ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0007.
    PubMed     Text format     Abstract available


  333. BALASUBRAMANIAN SK, Aly M, Nagata Y, Bat T, et al
    Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.
    Leukemia. 2018;32:550-553.
    PubMed     Text format    


  334. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
    Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
    Leukemia. 2018;32:364-375.
    PubMed     Text format     Abstract available


  335. STENGEL A, Kern W, Meggendorfer M, Nadarajah N, et al
    Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.
    Leukemia. 2018;32:295-302.
    PubMed     Text format     Abstract available


  336. KUBESOVA B, Pavlova S, Malcikova J, Kabathova J, et al
    Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
    Leukemia. 2018;32:450-461.
    PubMed     Text format     Abstract available


  337. DEANGELO DJ, George TI, Linder A, Langford C, et al
    Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
    Leukemia. 2018;32:470-478.
    PubMed     Text format     Abstract available


  338. LIU E, Tong Y, Dotti G, Shaim H, et al
    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Leukemia. 2018;32:520-531.
    PubMed     Text format     Abstract available


  339. MEYER C, Burmeister T, Groger D, Tsaur G, et al
    The MLL recombinome of acute leukemias in 2017.
    Leukemia. 2018;32:273-284.
    PubMed     Text format     Abstract available


  340. GARRIDO CASTRO P, van Roon EHJ, Pinhancos SS, Trentin L, et al
    The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Leukemia. 2018;32:323-331.
    PubMed     Text format     Abstract available


  341. KAUSHIK S, Liu F, Veazey KJ, Gao G, et al
    Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
    Leukemia. 2018;32:499-509.
    PubMed     Text format     Abstract available


    January 2018
  342. SUN X, Ren Y, Gunawan S, Teng P, et al
    Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099.
    Leukemia. 2018 Jan 30. pii: 10.1038/s41375-018-0020.
    PubMed     Text format    


  343. JO S, Lee JH, Mattei JJ, Barrett DM, et al
    Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
    Leukemia. 2018 Jan 5. pii: leu2017312. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  344. PIETTE C, Suciu S, Clappier E, Bertrand Y, et al
    Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.
    Leukemia. 2018;32:244-248.
    PubMed     Text format    


  345. BUONTEMPO F, McCubrey JA, Orsini E, Ruzzene M, et al
    Therapeutic targeting of CK2 in acute and chronic leukemias.
    Leukemia. 2018;32:1-10.
    PubMed     Text format     Abstract available


  346. BRAZDILOVA K, Plevova K, Skuhrova Francova H, Kockova H, et al
    Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.
    Leukemia. 2018;32:234-236.
    PubMed     Text format    


  347. BODDU P, Jorgensen J, Kantarjian H, Borthakur G, et al
    Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
    Leukemia. 2018;32:241-244.
    PubMed     Text format    


  348. GU S, Sayad A, Chan G, Yang W, et al
    SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Leukemia. 2018;32:203-213.
    PubMed     Text format     Abstract available


  349. MINGAY M, Chaturvedi A, Bilenky M, Cao Q, et al
    Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia.
    Leukemia. 2018;32:11-20.
    PubMed     Text format     Abstract available


  350. GOLE B, Mian E, Rall M, Wiesmuller L, et al
    Base excision repair proteins couple activation-induced cytidine deaminase and endonuclease G during replication stress-induced MLL destabilization.
    Leukemia. 2018;32:159-167.
    PubMed     Text format     Abstract available


  351. BROWN JR, Hillmen P, O'Brien S, Barrientos JC, et al
    Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
    Leukemia. 2018;32:83-91.
    PubMed     Text format     Abstract available


  352. VILLARESE P, Lours C, Trinquand A, Le Noir S, et al
    TCRalpha rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.
    Leukemia. 2018;32:61-71.
    PubMed     Text format     Abstract available


  353. SUN L, Shi Y, Wang G, Wang X, et al
    PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
    Leukemia. 2018;32:184-193.
    PubMed     Text format     Abstract available


  354. WELSH SJ, Churchman ML, Togni M, Mullighan CG, et al
    Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
    Leukemia. 2018;32:38-48.
    PubMed     Text format     Abstract available


    December 2017
  355. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
    Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).
    Leukemia. 2017 Dec 18. pii: leu2017341. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  356. BU J, Chen A, Yan X, He F, et al
    SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
    Leukemia. 2017 Dec 18. pii: leu2017339. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  357. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
    Chromothripsis in acute myeloid leukemia: Biological features and impact on survival.
    Leukemia. 2017 Dec 18. pii: leu2017351. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  358. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
    Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
    Leukemia. 2017 Dec 18. pii: leu2017350. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  359. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2017 Dec 12. pii: leu2017349. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  360. TIRADO-GONZALEZ I, Czlonka E, Nevmerzhitskaya A, Soetopo D, et al
    CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.
    Leukemia. 2017 Dec 6. pii: leu2017346. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  361. DRIESSEN EMC, de Lorenzo P, Campbell M, Felice M, et al
    Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.
    Leukemia. 2017;31:2854.
    PubMed     Text format     Abstract available


  362. GRZES KM, Swamy M, Hukelmann JL, Emslie E, et al
    Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
    Leukemia. 2017;31:2771-2779.
    PubMed     Text format     Abstract available


  363. GARCIA-MANERO G, Sekeres MA, Egyed M, Breccia M, et al
    A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts.
    Leukemia. 2017;31:2799-2806.
    PubMed     Text format     Abstract available


  364. TESIO M, Trinquand A, Ballerini P, Hypolite G, et al
    Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.
    Leukemia. 2017;31:2594-2600.
    PubMed     Text format     Abstract available


  365. ELDER A, Bomken S, Wilson I, Blair HJ, et al
    Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.
    Leukemia. 2017;31:2577-2586.
    PubMed     Text format     Abstract available


  366. DELGADO-MARTIN C, Meyer LK, Huang BJ, Shimano KA, et al
    JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Leukemia. 2017;31:2568-2576.
    PubMed     Text format     Abstract available


  367. RASCHE M, von Neuhoff C, Dworzak M, Bourquin JP, et al
    Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.
    Leukemia. 2017;31:2807-2814.
    PubMed     Text format     Abstract available


  368. ZHANG H, Reister Schultz A, Luty S, Rofelty A, et al
    Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.
    Leukemia. 2017;31:2752-2760.
    PubMed     Text format     Abstract available


  369. LYU Y, Lou J, Yang Y, Feng J, et al
    Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
    Leukemia. 2017;31:2543-2551.
    PubMed     Text format     Abstract available


  370. YOKOTA A, Hirai H, Shoji T, Maekawa T, et al
    Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.
    Leukemia. 2017;31:2742-2751.
    PubMed     Text format     Abstract available


    November 2017
  371. LABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2017 Nov 28. pii: leu2017337. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  372. NIMMAGADDA SC, Frey S, Edelmann B, Hellmich C, et al
    Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
    Leukemia. 2017 Nov 7. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  373. LHERMITTE L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, et al
    Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.
    Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  374. WALF-VORDERWULBECKE V, Pearce K, Brooks T, Hubank M, et al
    Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
    Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  375. HADZIJUSUFOVIC E, Albrecht-Schgoer K, Huber K, Hoermann G, et al
    Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
    Leukemia. 2017;31:2388-2397.
    PubMed     Text format     Abstract available


  376. PULIKKAN JA, Tenen DG, Behre G
    C/EBPalpha deregulation as a paradigm for leukemogenesis.
    Leukemia. 2017;31:2279-2285.
    PubMed     Text format     Abstract available


  377. LIU X, Rothe K, Yen R, Fruhstorfer C, et al
    A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.
    Leukemia. 2017;31:2376-2387.
    PubMed     Text format     Abstract available


  378. THIEL VN, Giaimo BD, Schwarz P, Soller K, et al
    Heterodimerization of AML1/ETO with CBFbeta is required for leukemogenesis but not for myeloproliferation.
    Leukemia. 2017;31:2491-2502.
    PubMed     Text format     Abstract available


  379. O'LEARY HA, Capitano M, Cooper S, Mantel C, et al
    DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.
    Leukemia. 2017;31:2468-2478.
    PubMed     Text format     Abstract available


  380. HOWARD DR, Munir T, McParland L, Rawstron AC, et al
    Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
    Leukemia. 2017;31:2416-2425.
    PubMed     Text format     Abstract available


  381. SAVINO AM, Sarno J, Trentin L, Vieri M, et al
    The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
    Leukemia. 2017;31:2365-2375.
    PubMed     Text format     Abstract available


  382. KRAMER AC, Kothari A, Wilson WC, Celik H, et al
    Dnmt3a regulates T-cell development and suppresses T-ALL transformation.
    Leukemia. 2017;31:2479-2490.
    PubMed     Text format     Abstract available


  383. ABRAHAM M, Klein S, Bulvik B, Wald H, et al
    The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
    Leukemia. 2017;31:2336-2346.
    PubMed     Text format     Abstract available


  384. HA VL, Luong A, Li F, Casero D, et al
    The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.
    Leukemia. 2017;31:2503-2514.
    PubMed     Text format     Abstract available


  385. DELL'AVERSANA C, Giorgio C, D'Amato L, Lania G, et al
    miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.
    Leukemia. 2017;31:2315-2325.
    PubMed     Text format     Abstract available


    October 2017
  386. SAID B, Gilles S, Weisdorf D, Rashidi A, et al
    The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia.
    Leukemia. 2017 Oct 31. doi: 10.1038/leu.2017.
    PubMed     Text format    


  387. YAN F, Shen N, Pang JX, Zhao N, et al
    A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.
    Leukemia. 2017 Oct 10. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  388. TOPP MS, Stelljes M, Zugmaier G, Barnette P, et al
    Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 9. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  389. JERCHEL IS, Hoogkamer AQ, Aries IM, Steeghs EMP, et al
    RAS pathway mutations as predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Oct 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  390. LI Z, Abraham BJ, Berezovskaya A, Farah N, et al
    APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
    Leukemia. 2017;31:2057-2064.
    PubMed     Text format     Abstract available


  391. MUNIR T, Howard DR, McParland L, Pocock C, et al
    Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Leukemia. 2017;31:2085-2093.
    PubMed     Text format     Abstract available


  392. JU HQ, Zhan G, Huang A, Sun Y, et al
    ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
    Leukemia. 2017;31:2143-2150.
    PubMed     Text format     Abstract available


  393. DUELL J, Dittrich M, Bedke T, Mueller T, et al
    Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
    Leukemia. 2017;31:2181-2190.
    PubMed     Text format     Abstract available


  394. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Text format     Abstract available


    September 2017
  395. FUJITA S, Honma D, Adachi N, Araki K, et al
    Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
    Leukemia. 2017 Sep 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  396. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2017 Sep 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  397. BENEDETTI D, Tissino E, Pozzo F, Bittolo T, et al
    NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-kB pathways.
    Leukemia. 2017 Sep 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  398. JO S, Lee JH, Mattei JJ, Barrett DM, et al
    Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  399. DEL GIUDICE I, Rigolin GM, Raponi S, Cafforio L, et al
    Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low and very-low risk genetic profile.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  400. NADEU F, Clot G, Delgado J, Martin-Garcia D, et al
    Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
    Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  401. HOSPITAL MA, Jacquel A, Mazed F, Saland E, et al
    RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  402. SAKURA T, Hayakawa F, Sugiura I, Murayama T, et al
    High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  403. WAIBEL M, Vervoort SJ, Kong IY, Heinzel S, et al
    Epigenetic targeting of Notch1 driven transcription using the HDACi panobinostat is a potential therapy against T cell acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  404. TAKAO S, Chien W, Madan V, Lin DC, et al
    Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Sep 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  405. MARNETH AE, Prange KHM, Al Hinai ASA, Bergevoet SM, et al
    C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
    Leukemia. 2017 Sep 5. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  406. RINKE J, Muller JP, Blaess MF, Chase A, et al
    Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
    Leukemia. 2017;31:1936-1943.
    PubMed     Text format     Abstract available


  407. KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
    The clonal origins of leukemic progression of myelodysplasia.
    Leukemia. 2017;31:1928-1935.
    PubMed     Text format     Abstract available


  408. SAENZ DT, Fiskus W, Qian Y, Manshouri T, et al
    Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Leukemia. 2017;31:1951-1961.
    PubMed     Text format     Abstract available


  409. RONCHINI C, Brozzi A, Riva L, Luzi L, et al
    PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.
    Leukemia. 2017;31:1975-1986.
    PubMed     Text format     Abstract available


    August 2017
  410. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
    Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Aug 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  411. JYOTSANA N, Sharma A, Chaturvedi A, Scherr M, et al
    RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.
    Leukemia. 2017 Aug 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  412. ZHAO L, Alkadi H, Kwon EM, Zhen T, et al
    The C-terminal multimerization domain is essential for leukemia development by CBFbeta-SMMHC in a mouse knockin model.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  413. TOFT N, Birgens H, Abrahamsson J, Griskevicius L, et al
    Results of NOPHO ALL2008 treatment for patients 1-45 years with acute lymphoblastic leukemia.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  414. PENA-MARTINEZ P, Eriksson M, Ramakrishnan R, Chapellier M, et al
    Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner.
    Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  415. KUMAR B, Garcia M, Weng L, Jung X, et al
    Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
    Leukemia. 2017 Aug 17. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  416. ARTESI M, Marcais A, Durkin K, Rosewick N, et al
    Monitoring molecular response in adult t-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.
    Leukemia. 2017 Aug 16. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  417. HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
    Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  418. HEHLMANN R, Lauseker M, Saussele S, Pfirrmann M, et al
    Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  419. REITER K, Polzer H, Krupka C, Maiser A, et al
    Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  420. MASCIARELLI S, Capuano E, Ottone T, Divona M, et al
    'Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress'.
    Leukemia. 2017 Aug 4. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  421. RAFIQ S, Purdon TJ, Daniyan AF, Koneru M, et al
    Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
    Leukemia. 2017;31:1788-1797.
    PubMed     Text format     Abstract available


  422. DRENNAN S, D'Avola A, Gao Y, Weigel C, et al
    IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.
    Leukemia. 2017;31:1686-1694.
    PubMed     Text format     Abstract available


    July 2017
  423. KIM HG, LeGrand J, Swindle CS, Nick HJ, et al
    The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  424. YIGIT B, Wang N, Chen SS, Chiorazzi N, et al
    Inhibition of Reactive oxygen species (ROS) limits expansion of chronic lymphocytic leukemia cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  425. TEH TC, Nguyen NY, Moujalled DM, Segal D, et al
    Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  426. GIRARDI T, Vereecke S, Sulima SO, Khan Y, et al
    The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  427. XIA F, Zhang Y, Xie L, Jiang H, et al
    B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  428. SOPPER S, Mustjoki S, Gjertsen BT, Giles F, et al
    NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.
    Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  429. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
    Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed     Text format    


  430. BECK D, Thoms JAI, Palu C, Herold T, et al
    A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
    Leukemia. 2017 Jul 4. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  431. HOURIGAN CS, Gale RP, Gormley NJ, Ossenkoppele GJ, et al
    Measurable residual disease testing in acute myeloid leukaemia.
    Leukemia. 2017;31:1482-1490.
    PubMed     Text format     Abstract available


  432. CUTLER JA, Tahir R, Sreenivasamurthy SK, Mitchell C, et al
    Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
    Leukemia. 2017;31:1513-1524.
    PubMed     Text format     Abstract available


  433. RIBEIRO ST, Tesio M, Ribot JC, Macintyre E, et al
    Casein kinase 2 controls the survival of normal thymic and leukemic gammadelta T cells via promotion of AKT signaling.
    Leukemia. 2017;31:1603-1610.
    PubMed     Text format     Abstract available


    June 2017
  434. ANGENENDT L, Reuter S, Kentrup D, Benk AS, et al
    An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  435. YABE T, Azuma F, Kashiwase K, Matsumoto K, et al
    HLA-DPB1 mismatch induces a graft-versus-leukemia (GVL) effect without severe acute GVHD after single-unit umbilical cord blood transplantation.
    Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  436. TIAO G, Improgo MR, Kasar S, Poh W, et al
    Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
    Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  437. GAIDZIK VI, Weber D, Paschka P, Kaumanns A, et al
    DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
    Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  438. ZHANG Q, Ball MC, Zhao Y, Balasis M, et al
    Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.
    Leukemia. 2017 Jun 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  439. RIO-MACHIN A, Gomez-Lopez G, Munoz J, Garcia-Martinez F, et al
    The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.
    Leukemia. 2017 Jun 20. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  440. GODWIN CD, Gale RP, Walter RB
    Gemtuzumab ozogamicin in acute myeloid leukemia.
    Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  441. SANTINI V, Allione B, Zini G, Gioia D, et al
    A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
    Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  442. BURNS A, Alsolami R, Becq J, Timbs A, et al
    Whole genome sequencing of chronic lymphocytic leukemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.
    Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  443. MARTINEZ-CUADRON D, Montesinos P, Vellenga E, Bernal T, et al
    Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
    Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  444. PROMOD ST, Johnson DP, Bennett SE, Dennis EM, et al
    HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2017 Jun 5. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  445. HAHN M, Burckert JP, Luttenberger CA, Klebow S, et al
    Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappaB signaling.
    Leukemia. 2017 Jun 1. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  446. USTUN C, Giannotti F, Zhang MJ, Wang HL, et al
    Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
    Leukemia. 2017;31:1408-1414.
    PubMed     Text format     Abstract available


  447. HERNDON TM, Chen SS, Saba NS, Valdez J, et al
    Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
    Leukemia. 2017;31:1340-1347.
    PubMed     Text format     Abstract available


  448. YAN F, Shen N, Pang JX, Zhang YW, et al
    Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.
    Leukemia. 2017;31:1434-1442.
    PubMed     Text format     Abstract available


  449. CHENG G, Liu F, Asai T, Lai F, et al
    Loss of p300 accelerates MDS-associated leukemogenesis.
    Leukemia. 2017;31:1382-1390.
    PubMed     Text format     Abstract available


  450. RODMAN C, Almeida-Porada G, George SK, Moon J, et al
    In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells.
    Leukemia. 2017;31:1398-1407.
    PubMed     Text format     Abstract available


  451. CARTER MJ, Cox KL, Blakemore SJ, Turaj AH, et al
    PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
    Leukemia. 2017;31:1423-1433.
    PubMed     Text format     Abstract available


    May 2017
  452. HALPERN AB, Othus M, Huebner EM, Buckley SA, et al
    Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  453. HA JS, Do YR, Ki CS, Lee C, et al
    Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  454. PATEL B, Przychodzen B, Thota S, Radivoyevitch T, et al
    Genomic determinants of chronic myelomonocytic leukemia.
    Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  455. HEILMANN AM, Schrock AB, He J, Nahas M, et al
    Novel PDGFRB fusions in childhood B and T acute lymphoblastic leukemia.
    Leukemia. 2017 May 29. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  456. MA Z, Zhao X, Huang J, Jia X, et al
    A critical role of periostin in B-cell acute lymphoblastic leukemia.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  457. BERNSON E, Hallner A, Sander FE, Wilsson O, et al
    Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  458. HINZE L, Moricke A, Zimmermann M, Junk S, et al
    Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  459. CHEN L, Mao H, Zhang J, Chu J, et al
    Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
    Leukemia. 2017 May 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  460. PAN J, Yang J, Deng B, Zhao X, et al
    High efficacy and safety of low dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Leukemia. 2017 May 11. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  461. ROSSETTI C, Picardi E, Ye M, Camilli G, et al
    RNA editing signature during myeloid leukemia cell differentiation.
    Leukemia. 2017 May 9. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  462. HASAN K, Yu J, Chen L, Cui B, et al
    Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  463. YU J, Chen L, Chen Y, Hasan K, et al
    Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
    Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  464. SLINGER E, Thijssen R, Kater AP, Eldering E, et al
    Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  465. LONG J, Fang WY, Chang L, Gao WH, et al
    Targeting HDAC3, new partner protein of AKT in the reversal of chemo-resistance in acute myeloid leukemia via DNA damage response.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  466. GUNNARSSON N, Hoglund M, Stenke L, Sandin F, et al
    No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia-a population-based study in Sweden.
    Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  467. EIRING AM, Page BDG, Kraft IL, Mason CC, et al
    Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Leukemia. 2017;31:1253-1254.
    PubMed     Text format    


  468. LEROY E, Constantinescu SN
    Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition.
    Leukemia. 2017;31:1023-1038.
    PubMed     Text format     Abstract available


  469. KAZIANKA L, Drucker C, Skrabs C, Thomas W, et al
    Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
    Leukemia. 2017;31:1117-1122.
    PubMed     Text format     Abstract available


  470. MALANI D, Murumagi A, Yadav B, Kontro M, et al
    Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
    Leukemia. 2017;31:1187-1195.
    PubMed     Text format     Abstract available


  471. LIU TH, Tang YJ, Huang Y, Wang L, et al
    Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin.
    Leukemia. 2017;31:1079-1086.
    PubMed     Text format     Abstract available


    April 2017
  472. CAZZANIGA G, Bisanti L, Randi G, Deandrea S, et al
    Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster.
    Leukemia. 2017 Apr 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  473. ROSENQUIST R, Ghia P, Hadzidimitriou A, Sutton LA, et al
    Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: Updated eric recommendations.
    Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  474. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
    Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  475. KONGTIM P, Adekola K, Milton DR, Ramlal R, et al
    Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Leukemia. 2017 Apr 12. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  476. HAN SH, Kim SH, Kim HJ, Lee Y, et al
    Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
    Leukemia. 2017 Apr 11. doi: 10.1038/leu.2017.
    PubMed     Text format    


  477. JONES D, Woyach JA, Zhao W, Caruthers S, et al
    PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  478. SILVA P, Neumann M, Schroeder MP, Vosberg S, et al
    Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
    Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  479. HEATH EM, Chan SM, Minden MD, Murphy T, et al
    Biological and clinical consequences of NPM1 mutations in AML.
    Leukemia. 2017;31:798-807.
    PubMed     Text format     Abstract available


  480. VALENT P, Sotlar K, Blatt K, Hartmann K, et al
    Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
    Leukemia. 2017;31:788-797.
    PubMed     Text format     Abstract available


  481. SCHUTZ C, Inselmann S, Sausslele S, Dietz CT, et al
    Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
    Leukemia. 2017;31:829-836.
    PubMed     Text format     Abstract available


    March 2017
  482. HEROLD S, Kuhn M, Bonin MV, Stange T, et al
    Donor cell leukemia-Evidence for multiple pre-leukemic clones and parallel long term clonal evolution in donor and recipient.
    Leukemia. 2017 Mar 28. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  483. ANADON C, van Tetering G, Ferreira HJ, Moutinho C, et al
    Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  484. COSSON A, Chapiro E, Bougacha N, Lambert J, et al
    Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: Analysis of the central role of XPO1.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  485. MONTALBAN-BRAVO G, Huang X, Naqvi K, Jabbour E, et al
    A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Text format    


  486. WALKER CJ, Eisfeld AK, Genutis LK, Bainazar M, et al
    No evidence for microsatellite instability in acute myeloid leukemia.
    Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  487. KAYSER S, Krzykalla J, Elliott MA, Norsworthy K, et al
    Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  488. ZHOU H, Mak PY, Mu H, Mak DH, et al
    Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  489. EISFELD AK, Mrozek K, Kohlschmidt J, Nicolet D, et al
    The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  490. POZZO F, Bittolo T, Vendramini E, Bomben R, et al
    NOTCH1 mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin-1 and ribosome associated components.
    Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


  491. KOEFFLER HP, Leong G
    Preleukemia: one name, many meanings.
    Leukemia. 2017;31:534-542.
    PubMed     Text format     Abstract available


  492. SAENZ DT, Fiskus W, Manshouri T, Rajapakshe K, et al
    BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Leukemia. 2017;31:678-687.
    PubMed     Text format     Abstract available


  493. QAZILBASH MH, Wieder E, Thall PF, Wang X, et al
    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
    Leukemia. 2017;31:697-704.
    PubMed     Text format     Abstract available


  494. STRUSKI S, Lagarde S, Bories P, Puiseux C, et al
    NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Leukemia. 2017;31:565-572.
    PubMed     Text format     Abstract available


  495. STENGEL A, Kern W, Haferlach T, Meggendorfer M, et al
    The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Leukemia. 2017;31:705-711.
    PubMed     Text format     Abstract available


  496. MCCRACKEN AN, McMonigle RJ, Tessier J, Fransson R, et al
    Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
    Leukemia. 2017;31:669-677.
    PubMed     Text format     Abstract available


  497. EDELMANN J, Tausch E, Landau DA, Robrecht S, et al
    Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
    Leukemia. 2017;31:734-738.
    PubMed     Text format    


    February 2017
  498. MEDEIROS BC, Fathi AT, DiNardo CD, Pollyea DA, et al
    Isocitrate dehydrogenase mutations in myeloid malignancies.
    Leukemia. 2017;31:272-281.
    PubMed     Text format     Abstract available


  499. BURNETT AK, Russell NH, Hills RK, Kell J, et al
    A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
    Leukemia. 2017;31:310-317.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: